Carlo Fremd

856 citations
25 papers · 455 indexed · h-index 12
Topics
Cancer Treatment and Pharmacology (6 papers)HER2/EGFR in Cancer Research (6 papers)Cancer Immunotherapy and Biomarkers (5 papers)

In The Last Decade

Carlo Fremd

23 papers receiving 445 citations

Peers

Carlo Fremd
Comparison fields: 5 of 76
  • Oncology 264
  • Immunology 131
  • Cancer Research 115
  • Molecular Biology 100
  • Pulmonary and Respiratory Medicine 69
Replace Aaron M. Muscarella with:
Aaron M. Muscarella United States
Yawen Ju United States
Elizabeth M. Chislock United States
Jenny Down United Kingdom
Qiongdan Zheng China
Sophie Thiolloy United States
Bo He China
Luana Lamura Italy
Mirella Georgouli United Kingdom
J. Carlos Trindade Filho United States
Carlo Fremd relative to Aaron M. Muscarella United States Aaron M. Muscarella's profile →
Citations per field
00.5×1.5×1.8×
Aaron M. Muscarella · 1×
Citations per year

Countries citing papers authored by Carlo Fremd

Since Specialization
Citations

This map shows the geographic impact of Carlo Fremd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carlo Fremd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carlo Fremd more than expected).

Fields of papers citing papers by Carlo Fremd

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carlo Fremd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carlo Fremd. The network helps show where Carlo Fremd may publish in the future.

Co-authorship network of co-authors of Carlo Fremd

This figure shows the co-authorship network connecting the top 25 collaborators of Carlo Fremd. A scholar is included among the top collaborators of Carlo Fremd based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carlo Fremd. Carlo Fremd is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 8
2 1
3 0
4 1
5 2
6 5
7 0
8 3
9 12
10 5
11 1
12 1
13 28
14 30
15 3
16 22
17 15
18 4
19 40
20 54

About Carlo Fremd

Carlo Fremd is a scholar working on Cancer Research, Oncology and Dermatology, having authored 25 papers that have together received 455 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (6 papers), HER2/EGFR in Cancer Research (6 papers) and Cancer Immunotherapy and Biomarkers (5 papers). The work is most often cited by research in Oncology (264 citations), Cancer Research (115 citations) and Immunology (131 citations). Carlo Fremd has collaborated with scholars based in Germany, United States and Switzerland. Frequent co-authors include Andreas Schneeweiß, Christoph Domschke, Florian Schuetz, Christof Sohn, Philipp Beckhove, Katharina Smetanay, Markus Wallwiener, Wolfram Wenz, Julia Seitz and Thomas Dreher. Their work appears in journals such as Cancer Research, Journal of Bone and Joint Surgery and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026